Details of the Drug Combination

General Information of Drug Combination (ID: DCCTL5N)

• Drug Combination Name: TG100801 + GDC-0084
• Indication: Ewing sarcoma; Status: Investigative [1]
• Component Drugs:
  TG100801 (DMPH1AG): Small molecular drug
  GDC-0084 (DMA9SEY): N.A.
• High-throughput Screening Result:
  Testing Cell Line: TC-71
  Zero Interaction Potency (ZIP) Score: 5.224
  Bliss Independence Score: 4.569
  Loewe Additivity Score: 0.802
  LHighest Single Agent (HSA) Score: 4.145

Molecular Interaction Atlas of This Drug Combination

Indication(s) of TG100801

Disease Entry	ICD 11	Status	REF
Macular degeneration	9B78.3	Phase 2	[2]

TG100801 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Vascular endothelial growth factor (VEGF)	TT9HKJA	VEGFA_HUMAN; VEGFB_HUMAN; VEGFC_HUMAN; VEGFD_HUMAN	Inhibitor	[4]

Indication(s) of GDC-0084

Disease Entry	ICD 11	Status	REF
Glioblastoma of brain	2A00.00	Phase 2	[3]

GDC-0084 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
PI3-kinase gamma (PIK3CG)	TTHBTOP	PK3CG_HUMAN	Inhibitor	[5]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] ClinicalTrials.gov (NCT00509548) Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT03522298) Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma. U.S. National Institutes of Health.
• [4] Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol. 2008 Jul;216(1):29-37.
• [5] Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012 July; 14(7): 819-829.